References

  1. Pilch H, Schlenger K, Steiner E, Brockerhoff P, Knapstein P, Vaupel P: Hypoxia-stimulated expression of angiogenic growth factors in cervical cancer cells and cervical cancer-derived fibroblasts.

    Int J Gynecol Cancer 2001 , 11:137-142. PubMed Abstract | Publisher Full Text OpenURL

  2. Kuroki M, Voest EE, Amano S, Berrepoot LV, Takashima S, Tolentino M, Kim RY, Rohan RM, Colby KA, Yeo K, Adamis AP: Reactive oxygen intermediates increase vascular endothelial growth factor expression in vitro and in vivo.

    J Clin Invest 1996 , 1667-1675. PubMed Abstract | Publisher Full Text | PubMed Central Full Text OpenURL

  3. Mukherjee A, Westwell AD, Bradshaw TD, Stevens MFG, Carmichael J, Martin SG: Cytotoxic and antiangiogenic activitiy of AW464 (NSC 706704) a novel thioredoxin inhibitor: an in vitro study.

    British Journal of Cancer 2005 , 92:350-358. PubMed Abstract | Publisher Full Text OpenURL

  4. Muller YA, Li B, Christinger HW, Wells JA, Cunningham BC, DeVos AM: Vascular endothelial growth factor: Crystal structure and functional mapping of the kinase domain receptor binding site.

    Proc Natl Acad Sci 1997 , 94:7192-7197. PubMed Abstract | Publisher Full Text | PubMed Central Full Text OpenURL

  5. Mohammed RAA, Green A, El-Shikh S, Paish EC, Ellis IO, Martin SG: Prognostic significance of vascular endothelial growth factors-A, -C, and -D in breast cancer and their relationship with angio- and lymphangiogenesis.

    British Journal of Cancer 2007 , (96):1092-1100. PubMed Abstract | Publisher Full Text OpenURL

  6. Shi YH, Bingle L, Gong LH, Wang YX, Corke KP, Fang WG: Basic FGF augments hypoxia induced HIF-1-alpha expression and VEGF release in T47D breast cancer cells.

    Pathology 2007 , 39(4):396-400. PubMed Abstract | Publisher Full Text OpenURL

  7. Yang JC, Haworth L, Sherr RM, Hwu P, Schwartzentruber DJ, Topalian SL, Steinberg SM, Chen HX, Rosenberg SA: A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cell cancer.

    The New England Journal of Medicine 2003 , 349(5):427-434. PubMed Abstract | Publisher Full Text | PubMed Central Full Text OpenURL

  8. Wang Y, Fei D, Vanderlaan M, Song A: Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro.

    Angiogenesis 2004 , 7:335-345. PubMed Abstract | Publisher Full Text OpenURL

  9. Hicklin DJ, Ellis LM: Role of Vascular Endothelial Growth Factor Pathway in Tumor Growth and Angiogenesis.

    Journal of Clinical Oncology 2005 , 23(5):1011-1027. PubMed Abstract | Publisher Full Text OpenURL

  10. Shweiki D, Itin A, Soffer D, Keshet E: Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis.

    Nature (6398):843-5. PubMed Abstract | Publisher Full Text OpenURL

    1992, Oct 29,

  11. Kim KJ, Li B, Winer J, Armanini M, Gillett N, Phillips HS, Ferrara N: Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo.

    Nature 1993 , 362:841-4. PubMed Abstract | Publisher Full Text OpenURL

  12. Brogi E, Schatteman G, Wu T, Kim EA, Varticovski L, Keyt B, Isner JM: Hypoxia-induced paracrine regulation of vascular endothelial growth factor receptor expression.

    J Clin Invest 1996 , 97(2):69-76. Publisher Full Text OpenURL

  13. Mukhopadhyay D, Tsiokas L, Zhou XM, Foster D, Brugge JS, Sukhatme VP: Hypoxic induction of human vascular endothelial growth factor expression through c-Src activation.

    Nature 357(6532):577-81. OpenURL

    1995 Jun 15,

  14. Kuhn H, Konrad J, Holtz S, Salsmeh A, Gessner C, Hammerschmidt S, Wirtz H: Enhanced expression of VEGF following bFGF inhibition in non-small cell lung cancer cell lines.

    Lung Cancer 2006 , 54(2):149-53. PubMed Abstract | Publisher Full Text OpenURL

  15. Cheng M, Li Y, Wu J, Nie Y, Li L, Liu X, Charoude HN, Chen H: IL-8 induces imbalances between nitric oxide and endothelin-1, and also between plasminogen activator inhibitor-1 and tissue-type plasminogen activator in cultured endothelial cells.

    Cytokine 2007 , in press. PubMed Abstract | Publisher Full Text OpenURL

  16. Petreaca ML, Yao M, Liu Y, Defea K, Martins-Green M: Transactivation of Vascular Endothelial Growth Factor Receptor-2 by Interleukin-8 (IL-8/CXCL8) is Required for IL-8/CXCL8-induced Endothelial Permeability.

    Mol Biol Cell 2007 , 18(12):5014-23. PubMed Abstract | Publisher Full Text | PubMed Central Full Text OpenURL

  17. Reinmuth N, Rensinghoff S, Raedel M, Fehrmann N, Schwöppe C, Kessler T, Bisping G, Hilberg F, Roth GJ, Berdel W, Thomas M, Mesters RM: Paracrine interactions of vascular endothelial growth factor and platelet-derived growth factor in endothelial and lung cancer cells.

    Int J Oncol 2007 , 31(3):621-6. PubMed Abstract | Publisher Full Text OpenURL

  18. Mourskaia AA, Northey JJ, Siegel PM: Targeting aberrant TGF-beta signaling in pre-clinical models of cancer.

    Anticancer Agents Med Chem 2007 , 7(5):504-14. PubMed Abstract | Publisher Full Text OpenURL

  19. De Luca A, Carotenuto A, Rachiglio A, Gallo M, Maiello MR, Aldinucci D, Pinto A, Normanno N: The role of the EGFR signaling in tumor microenvironment.

    J Cell Physiol 2007 , in press. OpenURL

  20. Harada S, Kimura T, Fujiki H, Nakagawa H, Ueda Y, Itoh T, Yamagishi H, Sonoda Y: Flt3 ligand promotes myeloid dendritic cell differentiation of human hematopoietic progenitor cells: possible application for cancer immunotherapy.

    Int J Oncol 2007 , 30(6):1461-8. PubMed Abstract | Publisher Full Text OpenURL

  21. Sato E, Fujimoto J, Toyoki H, Sakaguchi H, Alam SM, Jahan I, Tamaya T: Expression of IP-10 related to angiogenesis in uterine cervical cancers.

    Br J Cancer 2007 , 96(11):1735-9. PubMed Abstract | Publisher Full Text OpenURL

  22. Ignoffo RJ: Overview of bevacizumab: A new cancer therapeutic strategy targeting vascular endothelial growth factor.

    Am J Health-Syst Pharm 2004 , 61:S21-S26. PubMed Abstract | Publisher Full Text OpenURL

  23. Maghazachi AA, Al-Aoukaty A, Schall TJ: CC chemokines induce the generation of killer cells from CD56+ cells.

    Eur J Immunol 1996 , 26(2):315-9. PubMed Abstract | Publisher Full Text OpenURL

  24. Gallion H, Christopherson WA, Coleman RL, Demars L, Herzog T, Hosford S, Schellhas H, Wells A, Sevin B-U: Progression-free interval in ovarian cancer and predictive value of an ex vivo chemoresponse assay.

    Int J Gynecol Cancer 2006 , 16:194-201. PubMed Abstract | Publisher Full Text OpenURL

  25. Kenny PA, Bissel MJ: Tumor reversion: correction of malignant behaviour by microenvironmental cues.

    International Journal of Cancer (1):168-70. OpenURL

    2005, Jan 1,

  26. Kim JB, Stein R, O'Hare MJ: Three-dimensional in vitro tissue culture models of breast cancer – a review.

    Breast Cancer Research and Treatment 2004 , 85(3):281-91. Publisher Full Text OpenURL

  27. Heinzman JM, Brower SL, Bush JE: Ex vivo enrichment of malignant carcinoma cells in primary culture.

    Pathology 2007 , 39(5):491-4. PubMed Abstract | Publisher Full Text OpenURL

  28. Kornblith P, Ochs RL, Wells A, Gabrin MJ, Piwowar J, Chattopadhyay A, George LD, Burholt D: Differential in vitro effects of chemotherapeutic agents on primary cultures of human ovarian carcinoma.

    Int J Gynecol Cancer 2004 , 14:607-615. PubMed Abstract | Publisher Full Text OpenURL

  29. Hockel M, Vaupel P: Tumor Hypoxia: Definitions and Current Clinical, Biologic, and Molecular Aspects.

    Journal of the National Cancer Institute 2001 , 93(4):266-276. PubMed Abstract | Publisher Full Text OpenURL